Skip to main content
Premium Trial:

Request an Annual Quote

ADx Healthcare to Launch Alzheimer's Polygenic Risk Test Through Japanese Clinic

NEW YORK – Alzheimer's disease testing firm ADx Healthcare said today that it has partnered with Osaka, Japan-based Nakanoshima Clinic and Ixlayer, a San Francisco health IT company, to launch a polygenic-risk score for early detection of Alzheimer’s disease in Japan.

The test, called GenoRisk, assays 32 genetic loci, with results analyzed and interpreted by ADx Healthcare's medical team. According to the firm's CEO Steve Booth, the panel included both risk-associated and protective genes that influence Alzheimer's disease risk.

ADx has previously worked with Ixlayer to provide software and other services to create patient reports for direct-to-consumer Alzheimer's testing — in this case limited to the APOE gene — through consumer genomics firm Helix.

For the new polygenic risk test in Japan, ADx said that IxLayer's contribution will help ensure customers have access to clinicians throughout the process as well as educational information tailored to a patient's specific results.

"We have done extensive patient research here in the US on how to deliver this type of information to patients and are excited to tailor our product to patients located in Japan," IxLayer CEO Pouria Sanae said in a statement.

The Nakanoshima health center, which will market the test to its patients, is one of five clinics owned by the Shinyukai group, headquartered in Kyoto, Japan.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.